Please use this identifier to cite or link to this item:
|Title: ||Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson’s disease|
|Authors: ||Chen, Hwei-Hsien|
|Keywords: ||Apomorphine;Honokiol;6-Hydroxydopamine;Parkinson’s disease;Tyrosine hydroxylase|
|Issue Date: ||2018-07-24 16:49:46 (UTC+8)|
|Abstract: ||Background:Parkinson’s disease (PD) is a progressive and profound movement disorder resulting from neurodegeneration in the nigrostriatal dopaminergic system, but current treatment neither cures nor stops PD from advancing. Based on the ability to suppress oxidative stress, excitotoxicity, and neuroinflammation, the potential of honokiol as a novel neuroprotective agent for PD treatment was determined.Methods:|
The hemi-parkinsonian model was used to investigate the protective and therapeutic effects of honokiol on motor dysfunctions and dopaminergic neurodegeneration in mice, with a single unilateral striatal injection of 6-hydroxydopamine (6-OHDA).Results:One day after 6-OHDA-induced lesion, the mice exhibited spontaneous ipsilateral turning, motor imbalance, and incoordination which were mild with a single administration of honokiol prior to 6-OHDA injection. Thereafter, honokiol was continually applied daily for 14 days, which ameliorated apomorphine-induced contralateral rotation and reduced the loss of tyrosine hydroxylase-immunoreactive (TH-ir) fibers in the lesioned striatum. In addition, honokiol posttreatment, beginning on day 8 after 6-OHDA lesion, for 14 days efficiently rescued motor deficits and recovered the TH-ir neuronal loss in both the lesioned striatum and the ipsilateral substantia nigra. The 6-OHDA-induced increases in nigrostriatal expression of inducible nitric oxide synthase (iNOS) and decreases in that of nNOS were also reversed by honokiol posttreatment.Conclusions:These findings revealed that honokiol has both protective and therapeutic effects on motor impairments and dopaminergic progressive damage, at least in part through modulation of NOS signaling, in 6-OHDA-lesioned mice. Honokiol may represent a potential therapeutic candidate for the management of motor symptoms and neurodegeneration in PD.
|Relation: ||Pharmacological Reports,Volume 70, Issue 4, Pages 668-676|
|Data Type: ||article|
|DOI 連結: ||https://doi.org/10.1016/j.pharep.2018.01.003|
|Appears in Collections:||[神經科學研究所 ] 期刊論文|
Files in This Item:
All items in 政大典藏 are protected by copyright, with all rights reserved.